For example, in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study with patients of type 2 diabetes and nephropathy, 43.5% of participants in the losartan (ARB) group as compared with 47.1% in the placebo arm experienced doubling of serum creatinine concentration, ESRD, or death [10]. This evidence concerns the gene AGT and type 2 diabetes mellitus.